Skip To Main Content
Yingting Wei on Muck Rack

Yingting Wei

As seen in: Nature, Wiley Online Library, Epidemiology and Infection, Frontiers in Immunology, MDPI, European Journal of Obstetrics & Gynaecology and Reproductive Biology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yingting

Contact Yingting, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Cervi-LLM for real time colposcopy lesion detection and interpretable diagnosis

|
By Zhijun Hu, Ling Ma, Yingting Wei, Liying Gu, Zubei Hong, Yue Ding, Wen Di, Hongtao Lu, Lihua Qiu, Suizhi Huang, Anyue Wu
| Nature Verified
Abstract Colposcopy, a key procedure in cervical cancer screening for patients with abnormal TCT or HPV test results, requires extensive training for accurate diagnosis, yet diagnostic performance varies significantly across regions. This study presents Cervi-LLM, a multimodal MoE framework designed to assist in colposcopic detection by providing precise lesion localization and stratified diagnoses. The dataset included 126 cervical cancer, 692 HSIL, 306 LSIL, and 999 normal cases.
Open in Who Shared Issue with article?

Proteasome inhibition induces a BRCAness-like state and sensitises HR-proficient ovarian cancer models to PARP inhibitors

|
By Yingting Wei, Jing Niu, Jinghua Huang, Ruolan Wu, Kaiyan Gu, Anyue Wu, Lihua Qiu, Ruiju He
| Frontiers in Immunology
Abstract Background: Poly (ADP-ribose) polymerase inhibitors (PARPi) have improved outcomes in ovarian cancer with homologous recombination deficiency (HRD). However, approximately half of high-grade serous ovarian cancers retain intact homologous recombination repair and are classified as homologous recombination–proficient (HRP), limiting the clinical benefit of PARPi in this population.
Open in Who Shared Issue with article?

Efficacy of ALA‐PDT in treating cervical low‐grade squamous intraepithelial lesions with high‐risk HPV patients: A multicentre randomized controlled trial

|
By Yingting Wei, Liying Gu, Youzhong Zhang, Qiuyun Yang
| pericles.pericles-prod.literatumonline.com
CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest. REFERENCES 1, , , et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229-263. doi:10.3322/caac.21834 2, , , et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024; 4(1): 47-53. doi:10.1016/j.jncc.2024.01.006 3, , , , , .
Open in Who Shared Issue with article?
See all 10 articles